Twice-monthly certolizumab for plaque psoriasis could prove to be an option for patients who struggle with twice-weekly dosing, a study shows.
A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
Treating acne in pregnancy requires familiarity with FDA medication categories and having thorough discussions with patients.
Between 2004 and 2013, the number of spironolactone courses per 100 females with acne rose from 2.08 to 8.13 among dermatologists and from 1.43 to 4.09 among nondermatologists, researchers report.
Initial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
The transgender dermatology patient may face a unique set of challenges doctors should be prepared to address, says Dr. Brian Ginsberg.
Injectable aesthetic products recently FDA-approved or in late stages of development include polycaprolactone, a new hyaluronic acid and multiple neuromodulators.
Speaking at the American Academy of Dermatology annual meeting in February, Dr. Brett Coldiron described challenges dermatologists should be prepared for this year, including Medicare payment reductions, insurers' cost-saving strategies and practice consolidations.
There's been much debate in the literature about the need for and role of vitamin D, which may encourage patients to overdo vitamin dosing, researchers said at AAD 2018 this week.